![Graham Collins: Starglo – A practice changing study](https://oncodaily.com/pub/uploads/2024/06/Graham-Collins-f-1280x721.jpg)
Photo taken from Graham Collins/X
Jun 19, 2024, 07:45
Graham Collins: Starglo – A practice changing study
Graham Collins, Associate Professor of Hematology at the Oxford Cancer and Hematology Center shared a post on X:
“Starglo – EHA2024 plenary:
- R-GemOx vs. Glofit-GemOx R/R DLBCL
- 2L (SCT-ineligible) / 3L+
- OS primary EP
- Med OS 12.9 months (con) vS 25.5 months
- More TEAEs but more Rx exposure
- More deaths but mainly COVID
- G1/2 CRS as expected
A practice-changing study. ”
Source: Graham Collins/X
Jul 1, 2024, 19:16